Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Am Dent Assoc. 2011 Mar;142(3):262–273. doi: 10.14219/jada.archive.2011.0165

Figure 3. SDD effects on serum MMP-9 over the two-year clinical trial.

Figure 3

SDD significantly reduced mean serum MMP-9 (92 kDa) by 28.44 scanning units over the two-year protocol relative to placebo after adjustment for the baseline MMP-9 (92 kDa) level, smoking status, study center, study visit and batch effects (p<0.0001, intent-to-treat analysis). Data are expressed as mean ± 95% confidence interval for the mean. The number of subjects analyzed at each time point in the placebo group is as follows: 62 at baseline, 61 at the 1-year visit (serum sample not available for one subject) and 62 at the two-year visit. 51 subjects were analyzed at each time point in the SDD group. MMP-9 = matrix metalloproteinase-9.